The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Impact biotech; Steba biotech
A phase 3 multicenter study to evaluate the safety and efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in treatment of low-grade (LG) upper tract urothelial cancer (UTUC).
 
Jonathan Coleman
Travel, Accommodations, Expenses - Digital Angiography Reading Center (I)
(OPTIONAL) Uncompensated Relationships - AngioDynamics; Steba Biotech
 
Vitaly Margulis
No Relationships to Disclose
 
Avigdor Joshua Scherz
No Relationships to Disclose
 
Inna Krasnopolskaya
Employment - Sotio; Steba Biotech
 
Genia Alpert
No Relationships to Disclose
 
Veronique Jobert
No Relationships to Disclose
 
Dina Preise
No Relationships to Disclose
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure